The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
Toyama Chemical and Eisai Receive Approval to Market
Anti-rheumatic Agent Iguratimod in Japan
|June 29, 2012|
Toyama Chemical Co., Ltd. (Headquarters: Tokyo, President: Masuji Sugata, “Toyama Chemical”) and Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that they have received approval from Japan’s Ministry of Health, Labour and Welfare to market iguratimod (generic name; development code: T-614) for the treatment of rheumatoid arthritis.
Iguratimod, originally discovered by Toyama Chemical, is a novel disease modifying anti-rheumatic drug (DMARD) jointly developed in Japan by Toyama Chemical and Eisai based on a co-development and license agreement previously concluded between the two companies.
In a clinical study of iguratimod administered as a monotherapy in patients with rheumatoid arthritis, the agent demonstrated superiority over placebo and non-inferiority compared to an existing DMARD (salazosulfapyridine). In addition, in a trial of iguratimod in combination with methotrexate (“MTX”), the standard of care, conducted in rheumatoid arthritis patients who did not achieve satisfactory benefit with MTX alone, patients who were administered a combination of the two agents demonstrated favorable tolerability as well as significant improvements compared to those treated with placebo (MTX-only arm) in the study's primary endpoint of ACR20 response rate at Week 24. Out of all the orally-administered anti-rheumatic drugs currently approved in Japan, iguratimod is the first agent evaluated in domestic clinical trials to demonstrate efficacy as an add-on therapy to MTX in patients who did not achieve satisfactory benefit with MTX alone.
Once listed on Japan’s National Health Insurance (NHI) drug price list, iguratimod will be sold by Taisho Toyama Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Akira Ohira) and Eisai under the brand names KOLBET® Tablets 25 mg and Careram® Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use.
By providing iguratimod as a new option for the pharmacological treatment of rheumatoid arthritis, Toyama Chemical and Eisai believe that they will be able to make further contributions to address the diversified needs and improve the quality of life of rheumatoid arthritis patients.
[Please refer to the following notes for a product outline, further information on iguratimod clinical trials and a glossary of terms]
≪Notes to editors≫
1. Product Outline
2. About the Iguratimod-MTX Combination Trial
3. Rheumatoid Arthritis
4. Disease Modifying Anti-Rheumatic Drug (DMARD)
5. ACR20 Response Rate